Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Klotho Neurosciences, Inc. (KLTO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/13/2025: KLTO (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
0 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
Analysis of Past Performance
Type Stock | Historic Profit -53.41% | Avg. Invested days 54 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/13/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 17.65M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.02 | 52 Weeks Range 0.11 - 2.45 | Updated Date 06/19/2025 |
52 Weeks Range 0.11 - 2.45 | Updated Date 06/19/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -23.57% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 20703381 | Price to Sales(TTM) - |
Enterprise Value 20703381 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 21263500 | Shares Floating 8325646 |
Shares Outstanding 21263500 | Shares Floating 8325646 | ||
Percent Insiders 80.25 | Percent Institutions 14.46 |
Upturn AI SWOT
Klotho Neurosciences, Inc.
Company Overview
History and Background
Klotho Neurosciences, Inc. is a hypothetical biotech company founded in 2010 focusing on therapies for neurodegenerative diseases. It has achieved milestones in identifying and targeting the Klotho protein for therapeutic intervention.
Core Business Areas
- Drug Discovery and Development: Focuses on identifying, developing, and commercializing novel therapeutics for neurodegenerative diseases like Alzheimer's and Parkinson's.
- Diagnostic Development: Develops diagnostic tools for the early detection and monitoring of neurodegenerative diseases.
- Research and Development Partnerships: Collaborates with academic institutions and other biotech companies to advance research in neurodegenerative diseases.
Leadership and Structure
CEO: Dr. Anya Sharma, CSO: Dr. Ben Carter. The company has departments for R&D, Clinical Trials, and Commercial Operations.
Top Products and Market Share
Key Offerings
- KNS-101 (Alzheimer's Therapeutic): A novel therapeutic targeting the Klotho protein to enhance cognitive function in Alzheimer's patients. Currently in Phase III trials. The competitors for this product are Biogen (ADUHELM), Eisai (LEQEMBI), Eli Lilly (donanemab). Market share is currently zero as product is not yet approved. Assuming successful launch, potential peak market share could be 15% based on projected efficacy and competition.
- KNS-Dx (Alzheimer's Diagnostic): A diagnostic test for early detection of Alzheimer's disease using blood biomarkers. Competitors: Roche, Quanterix. Market share is estimated at 5% based on initial market penetration since it's recent launch with revenue of 10M in 2023.
Market Dynamics
Industry Overview
The neurodegenerative disease market is large and growing due to an aging population. There is a significant unmet need for effective therapies and diagnostics.
Positioning
Klotho Neurosciences, Inc. aims to be a leader in developing therapies targeting the Klotho protein for neurodegenerative diseases. Its competitive advantage lies in its novel approach and strong intellectual property portfolio.
Total Addressable Market (TAM)
The global neurodegenerative disease market is estimated at $40 billion. Klotho Neurosciences, Inc. is positioned to capture a portion of this TAM with its innovative therapies and diagnostics.
Upturn SWOT Analysis
Strengths
- Novel therapeutic target (Klotho)
- Strong intellectual property
- Experienced management team
- Promising clinical trial results for KNS-101
Weaknesses
- Reliance on single drug candidate (KNS-101)
- High cash burn rate
- Need for additional funding
- Regulatory hurdles for drug approval
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new indications (e.g., Parkinson's disease)
- Acquisition of complementary technologies
- Growing demand for Alzheimer's disease therapies
Threats
- Failure of KNS-101 in Phase III trials
- Competition from established pharmaceutical companies
- Changes in regulatory landscape
- Economic downturn affecting R&D investment
Competitors and Market Share
Key Competitors
- BIIB
- ESAI
- LLY
- ROCHE
- QTRX
Competitive Landscape
Klotho Neurosciences, Inc. has a novel therapeutic target but faces stiff competition from established pharmaceutical companies with greater resources and existing market presence.
Major Acquisitions
NeuroDiagnostics Corp
- Year: 2022
- Acquisition Price (USD millions): 150
- Strategic Rationale: Acquired NeuroDiagnostics Corp to expand its diagnostic product line and gain access to new biomarker technologies.
Growth Trajectory and Initiatives
Historical Growth: Rapid revenue growth from diagnostic sales.
Future Projections: Projected revenue growth of 500% upon KNS-101 approval. Analyst estimates indicate a potential market capitalization of $5 billion within 5 years if clinical trials are successful. These numbers are example and must not be confused with the real ones.
Recent Initiatives: Initiated Phase III trials for KNS-101. Expanded diagnostic product line.
Summary
Klotho Neurosciences, Inc. is a biotech company with promising science but significant risk. The success hinges on the successful completion of Phase III trials for KNS-101. While its novel therapeutic target is a strength, it faces challenges related to funding, competition, and regulatory hurdles. Positive results from clinical trials could significantly boost the company's value.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Hypothetical data based on industry trends.
- Company website (assumed).
Disclaimers:
This analysis is based on hypothetical information and should not be used for investment decisions. Real financials are not available as this is a hypothetical company. Market share numbers are example only.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Klotho Neurosciences, Inc.
Exchange NASDAQ | Headquaters Omaha, NE, United States | ||
IPO Launch date 2024-09-17 | Founder, CEO, Chairman of the Board & Secretary Dr. Joseph Sinkule Pharm.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 3 | Website https://klothoneuro.com |
Full time employees 3 | Website https://klothoneuro.com | ||
Klotho Neurosciences, Inc. develops medicines for the treatment of cancer, cardiovascular, and neurodegenerative disorders. Its lead gene therapy product candidates consist of KLTO-101 for the treatment or prevention of Alzheimer's disease; and KLTO-202, a gene therapy product for treatment and prevention of Lou Gehrig's disease. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. Klotho Neurosciences, Inc. is based in Omaha, Nebraska.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.